AI Tokens
Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Analysis of Long-term (Investment) Activity Ratios

Microsoft Excel

Long-term Activity Ratios (Summary)

Celgene Corp., long-term (investment) activity ratios

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net fixed asset turnover 11.17 12.12 12.03 11.25 11.77
Total asset turnover 0.43 0.43 0.40 0.34 0.44
Equity turnover 2.48 1.87 1.69 1.55 1.16

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).


The investment activity ratios from 2014 to 2018 reveal a divergence between the efficiency of fixed asset utilization and the efficiency of equity utilization. While fixed and total asset turnover remained relatively stagnant or showed modest recovery, equity turnover experienced aggressive and consistent growth.

Net Fixed Asset Turnover
The net fixed asset turnover remained relatively stable throughout the analyzed period, fluctuating within a narrow range between 11.17 and 12.12. A slight dip occurred in 2015, followed by a peak in 2017, before returning to 11.17 in 2018. This stability indicates that the company maintained a consistent level of revenue generation relative to its investment in fixed assets.
Total Asset Turnover
A V-shaped trend is observed in total asset turnover. After starting at 0.44 in 2014, the ratio declined to 0.34 in 2015, representing a decrease in overall asset efficiency. However, a steady recovery followed, with the ratio climbing back to 0.43 by 2017 and maintaining that level through 2018. The absolute values remain low, suggesting a capital-intensive structure where total assets are high relative to annual sales.
Equity Turnover
A strong and continuous upward trend is evident in the equity turnover ratio, which rose from 1.16 in 2014 to 2.48 in 2018. This represents more than a twofold increase in the efficiency with which shareholders' equity is used to generate revenue. The consistent year-over-year growth suggests an increasing reliance on equity leverage or a significant acceleration in revenue growth that outpaced the growth of equity.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Net Fixed Asset Turnover

Celgene Corp., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net product sales 15,265 12,973 11,185 9,161 7,564
Property, plant and equipment, net 1,367 1,070 930 814 643
Long-term Activity Ratio
Net fixed asset turnover1 11.17 12.12 12.03 11.25 11.77
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Net fixed asset turnover = Net product sales ÷ Property, plant and equipment, net
= 15,265 ÷ 1,367 = 11.17

2 Click competitor name to see calculations.


A sustained period of growth is evident from 2014 through 2018, characterized by a strong correlation between revenue increases and the expansion of the fixed asset base. The synchronization of these two metrics suggests a disciplined approach to capital expenditure in relation to sales scaling.

Analysis of Sales and Capital Investment
Net product sales increased linearly, rising from 7,564 million US$ in 2014 to 15,265 million US$ in 2018. This expansion was supported by a continuous increase in net property, plant, and equipment, which grew from 643 million US$ to 1,367 million US$ over the same duration. The proportional increase in assets suggests that investment in infrastructure was strategically deployed to accommodate growing sales volume.
Evaluation of Net Fixed Asset Turnover
The net fixed asset turnover ratio remained remarkably stable throughout the five-year period, fluctuating within a narrow range between 11.17 and 12.12. The absence of a significant trend indicates that the efficiency of fixed asset utilization remained constant despite the overall increase in company scale. While the ratio peaked at 12.12 in 2017, a decline to 11.17 in 2018 suggests that the growth in net property, plant, and equipment slightly outpaced the growth in sales during that specific fiscal year.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Total Asset Turnover

Celgene Corp., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net product sales 15,265 12,973 11,185 9,161 7,564
Total assets 35,480 30,141 28,086 27,053 17,340
Long-term Activity Ratio
Total asset turnover1 0.43 0.43 0.40 0.34 0.44
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Total asset turnover = Net product sales ÷ Total assets
= 15,265 ÷ 35,480 = 0.43

2 Click competitor name to see calculations.


Between 2014 and 2018, a consistent upward trend in net product sales is observed, with revenue increasing from US$ 7,564 million to US$ 15,265 million. This growth was accompanied by a substantial expansion of the total asset base, which grew from US$ 17,340 million to US$ 35,480 million over the same period. The relationship between these two metrics is reflected in the total asset turnover ratio, which exhibited a period of volatility followed by stabilization.

Revenue and Asset Growth Patterns
Net product sales demonstrated steady annual growth throughout the analyzed period. In contrast, total assets experienced a significant surge between 2014 and 2015, increasing by approximately 56%. Subsequent years showed a more moderate but continuous increase in total assets.
Asset Turnover Efficiency
The total asset turnover ratio declined from 0.44 in 2014 to 0.34 in 2015, a movement that corresponds with the rapid increase in total assets outpacing the growth in sales. This suggests a temporary decrease in asset utilization efficiency during the heavy investment phase of 2015.
Recovery and Stabilization
Following the 2015 low, the turnover ratio recovered to 0.40 in 2016 and reached 0.43 by 2017, remaining constant at that level through 2018. This indicates that the company successfully optimized its expanded asset base to generate higher sales volumes, eventually returning to a level of efficiency nearly identical to the 2014 baseline.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Equity Turnover

Celgene Corp., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net product sales 15,265 12,973 11,185 9,161 7,564
Stockholders’ equity 6,161 6,921 6,599 5,919 6,525
Long-term Activity Ratio
Equity turnover1 2.48 1.87 1.69 1.55 1.16
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Equity turnover = Net product sales ÷ Stockholders’ equity
= 15,265 ÷ 6,161 = 2.48

2 Click competitor name to see calculations.


An analysis of the period from 2014 to 2018 reveals a significant and consistent improvement in the efficiency with which equity is utilized to generate revenue. The equity turnover ratio exhibited a steady upward trajectory, more than doubling over the five-year period, which indicates a strong increase in operational productivity relative to the company's equity base.

Net Product Sales Trend
Revenue demonstrated robust and uninterrupted growth, increasing from US$ 7,564 million in 2014 to US$ 15,265 million in 2018. This continuous expansion reflects a substantial increase in the scale of operations and market penetration over the analyzed timeframe.
Stockholders' Equity Dynamics
The equity base remained relatively stable, characterized by moderate fluctuations rather than a clear growth trend. Equity decreased in 2015, reached a peak of US$ 6,921 million in 2017, and subsequently declined to US$ 6,161 million by the end of 2018. This indicates that the company did not rely on significant equity expansion to fund its growth.
Equity Turnover Ratio Analysis
The equity turnover ratio rose progressively from 1.16 in 2014 to 2.48 in 2018. Because net sales grew aggressively while stockholders' equity remained stagnant or declined, the ratio accelerated. This pattern suggests that the company became increasingly effective at generating sales per dollar of equity, reflecting high capital efficiency and an optimized investment structure.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?